
Digital and spatial characterization of PD-L1 expression and IVD assay performance in the immune landscape of head and neck squamous cell carcinoma: A multimodal approach (Poster No. 6634 at #AACR2023)
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive

Macrophage Biomarkers CD68 and CD163 Correlate with NSCLC Patient Survival (Poster No. 1720 at #AACR2022)
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates

Macrophage Biomarkers CD68 and CD163 Correlate with CRC Patient Survival (Poster No. 2530 at #AACR2022)
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’

Virtual Centralized Pathology = More Accurate Patient Data (Poster No. 10018 at Digital Pathology Association’s Pathology Visions 2021 #pathvisions21)
Background Historically, immunohistochemistry (IHC) assays have been designed for simplicity of manual pathology, however, this is not always ideal to acquire the appropriate data for

Original Research Article (Pfizer): First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors
In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article

Original Research Article: Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors
In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was